Dual Target CAR-T Cells in B-cell Lymphoma

Inclusion Criteria:

• Subjects must meet the following criteria to participate in this study:

1. 14-75 years old, no gender limit;
2. Diagnosed as relapsed/refractory B-cell lymphoma according to the 2020 WorldHealth Organization (WHO) diagnostic criteria;
3. ECOG behavior status score is 0-2 points;
4. Expected survival time ≥ 3 months;
5. No contraindications to peripheral apheresis;
6. Flow cytometry/immunohistochemistry confirms that tumor cells express CD20;
7. Those who are tolerant to CD19 CAR-T cell therapy or those with low CD19expression;
8. No serious heart, lung, liver or kidney disease;
9. Ability to understand and willing to sign the informed consent form for thistrial.

Exclusion Criteria:

• Patients with any of the following cannot be included in this study:

1. Tumor cells do not express CD20;
2. There is active infection;
3. Abnormal liver function (total bilirubin>1.5×ULN, glutamic-pyruvictransaminase>2.5×ULN), abnormal renal function (serum creatinine>1.5×ULN);
4. People with unstable angina or New York Heart Association class 3/4 congestiveheart failure, multiple organ dysfunction;
5. HIV/AIDS patients;
6. Those who need long-term anticoagulation (warfarin or heparin), antiplatelet (aspirin, dose>300mg/d; clopidogrel, dose>75mg/d) treatment;
7. Those who received radiotherapy within 4 weeks before the start of the study (blood sampling);
8. Known or suspected drug abuse or alcohol dependence;
9. People with mental illness or other conditions cannot obtain informed consent,and cannot cooperate with the requirements for completing the experimentaltreatment and inspection procedures;
10. Those who have participated in other clinical trials within 30 days;
11. Pregnant or lactating women, male subjects (or their partners) or female subjectshave a pregnancy plan during the study period to 6 months after the end of thetest, and are unwilling to use a medically approved effective contraceptivemeasure during the test period (Such as intrauterine device or condom);
12. The investigator judged that it is not suitable to participate in this trial.